[DOWNLOAD] "Monitoring Response to Therapy in Rheumatoid Arthritis: Perspectives from the Clinic." by Bulletin of the NYU Hospital for Joint Diseases ~ eBook PDF Kindle ePub Free

📘 Read Now     📥 Download

eBook details

• Title: Monitoring Response to Therapy in Rheumatoid Arthritis: Perspectives from the Clinic.
• Author : Bulletin of the NYU Hospital for Joint Diseases
• Release Date : January 01, 2009
• Genre: Health & Fitness,Books,Health, Mind & Body,
• Pages : * pages
• Size : 226 KB

Description

Rheumatoid arthritis (RA) is a debilitating inflammatory disease with clinical signs and symptoms that include swollen joints, cartilage and bone damage, morning stiffness, and loss of physical function. (1) Consequently, patients with severe disease face significant disability, deformity, and irreversible joint damage. (1) This chronic condition can also have a significant negative impact on patients' health-related quality of life (HRQoL), with many patients experiencing fatigue, decreased sleep quality, depression, and reduced work productivity. (2,3) Taken together, these symptoms have a detrimental impact on the patient's physical, social, psychological, and economic well-being. There are two main goals for the treatment of RA by rheumatology healthcare practitioners (HCPs). The first is to make the patient feel better by managing the symptoms of the disease, and the second is to secure the patient's future by preserving their joint function, with the ultimate goal of remission. (4,5) Disease-modifying antirheumatic drugs (DMARDs) used in the treatment of RA have the potential to reduce and prevent joint damage, as well as to preserve joint integrity and function in patients. (1) Nonsteroidal antiinflammatory drugs (NSAIDs) and corticosteroids are often used as supplemental therapies to help manage the symptoms of the disease. (1) Of the currently available DMARDs, traditional nonbiologic therapies include methotrexate, hydroxychloroquine, sulfasalazine, and leflunomide, and biologic therapies include the tumor necrosis factor antagonists etanercept, infliximab, and adalimumab. Other biologic agents include the selective T-cell modulator abatacept, the B-cell depleting therapy rituximab, and the interleukin-1 antagonist anakinra. (1,6) Traditional and biologic DMARDs have helped many patients to manage their disease. (5)

PDF Ebook Download "Monitoring Response to Therapy in Rheumatoid Arthritis: Perspectives from the Clinic." Online ePub Kindle